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TreatmentPulmonary hypertension (PH), increasingly recognized as a major health burden, remains underdiagnosed
due mainly to the unspeciﬁc symptoms. Pulmonary arterial hypertension (PAH) has been extensively
investigated. Pathophysiological knowledge derives mostly from experimental models. Paradoxically,
common non-PAH PH forms remain largely unexplored. Drugs targeting lung vascular tonus became
available during the last two decades, notwithstanding the disease progresses in many patients. The aim of
this review is to summarize recent advances in epidemiology, pathophysiology and management with
particular focus on associated myocardial and systemic compromise and experimental therapeutic
possibilities. PAH, currently viewed as a panvasculopathy, is due to a crosstalk between endothelial and
smooth muscle cells, inﬂammatory activation and altered subcellular pathways. Cardiac cachexia and right
ventricular compromise are fundamental determinants of PH prognosis. Combined vasodilator therapy is
already mainstay for refractory cases, but drugs directed at these new pathophysiological pathways may
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Pulmonary hypertension (PH), is deﬁned by mean pulmonary
arterial (PA) pressure (mPAP) elevation above 25 mmHg at rest [1]. In
most cases, PH accompanies cardio-respiratory conditions and does
not involve the pulmonary vasculature. However, more rarely it may
present itself as pulmonary arterial hypertension (PAH), deﬁnedadditionally by normal left ventricular (LV) ﬁlling pressure [2]. PAH is
viewed as a vasoproliferative disease with characteristic pathological
abnormalities, such as arteriolar plexiform lesions, as found in most of
cases. Initial symptoms, mainly fatigue and dyspnea, are usually vague
and insidious, thus most cases are diagnosed when cardiac output
(CO) is already low [3]. Right ventricular (RV) failure due to PH is an
important cause of death [4] whose complex pathophysiologicalalk test; AC, adenylate cyclase; AS, atrial septostomy; BMP, bone
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ng transplantation; MCP-1, monocyte chemotactic protein-1; MLC,
etalloproteinases; mPAP, mean pulmonary artery pressure; NFAT,
ized clinical trial; O2. -, superoxide anion; PA, pulmonary arterial;
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5 phosphodiesterase; PDEi, phosphodiesterase inhibitors; PDGF,
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f life; RANTES, regulated upon activation, normal T expressed and
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tor; TnC, tenascin C; TNF-α, tumor necrosis factor-α; trp, transient
factor; VEGR, vascular endothelial growth factor receptor; WHO,
ity Hospital São João, Alameda Professor Hernâni Monteiro, 4200–
Table 1
New classiﬁcation for pulmonary hypertension (PH) from the 4th World Symposium on PH (Dana Point, 2008).
Pulmonary arterial hypertension
(PAH)
Non-PAH pulmonary hypertension (PH)
Well deﬁned cause Unclear or multifactorial
PAH (1) Left-heart disease (2) Unclear/multifactorial mechanisms (5)
Idiopathic Systolic dysfunction Haematologic disorders
Hereditary Diastolic dysfunction Myeloproliferative disorders, etc.
Drug/toxin induced Valvular disease Systemic disorders
Disease associated Lung diseases/hypoxia (3) Vasculitis, sarcoidosis, neuroﬁbromatosis, etc.
CTD COPD Metabolic disorders
HIV infection Interstitial lung disease Glycogen storage disease, thyroid disorders, etc.
Portal hypertension Sleep-disordered breathing Congenital heart disease
Systemic-pulmonary shunts Chronic exposure to high altitude (Other than systemic-pulmonary shunt)
Schistosomiasis Broncho pulmonary dysplasia Other
Chronic haemolytic anaemia Developmental abnormalities Fibrosing mediastinitis, chronic renal failure on dialysis, etc.
Subclass of PAH (1′) CTEPH (4)
PVOD and PCH
Classes are presented between parentheses. CTD, connective tissue disease; HIV, human immunodeﬁciency virus; PVOD, pulmonary veno-occlusive disease; PCH, pulmonary
capillary angiomatosis; COPD, chronic obstructive pulmonary disease; CTEPH, chronic thromboembolic PH.
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have been proliﬁc in experimental and clinical studies in both PAH
and PH. Several new drugs have become available [3]. Nevertheless,
the prognosis remains poor, and many patients require transplanta-
tion [5]. The present review aims to summarize the most recent
concepts on the epidemiology, pathophysiology, diagnosis and man-
agement of PH [6,7].
2. Aetiology and classiﬁcation
Several conferences on PH have been fostered by theWorld Health
Organization (WHO). A classiﬁcation was proposed in 1973 and then
modiﬁed at Evian in 1988 to better reproduce pathophysiology and
clinical presentation. At Venice in 2003, the term primary PH was
substituted for idiopathic PAH (iPAH) and pulmonary veno-occlusive
disease (PVOD) and pulmonary capillary haemangiomatosis (PCH)
were grouped under a single PAH subcategory. In 2008, the 4thWorld
Symposium held in Dana Point (Table 1) endorsed the expression
“non-PAH PH” to address categories other than PAH. Additionally,
left-heart disease PH was subdivided in systolic heart failure (HF),
diastolic HF and valvular heart disease, and schistosomiasis was
included as a new class of disease-associated PAH.
3. Diagnosis
During the 4th Conference (Table 2) exercise valueswere excluded
as a criteria for diagnosis since the increase in mPAP during exercise
frequently exceeds 30 mm Hg among the elderly [8]. Additionally,
non-invasive echocardiographic criteria of systolic tricuspid regur-
gitant velocity were contemplated [9]. Nevertheless, transpulmonary
ﬂow and pulmonary venous pressure are not reliably measured by
echocardiography thus right-heart catheterisation (RHC) remains the
gold standard while echocardiography is usually a screening exam.
RHC is mandatory in every patient, allowing the selection of patients
that may beneﬁt from Ca2+-channel blockers (CCB), the positive
responders during vasoreactivity test, those in whom mPAP drops
more than 10 mm Hg or to values bellow 40 mm Hg with normal orTable 2
New diagnostic criteria for pulmonary hypertension (PH) from the 4th World
Symposium on PH (Dana Point, 2008).
Method Normal Borderline Clear
mPAP (mm Hg) b21 21–25 N25
systolic tricuspid regurgitation (m.s−1) b2.5 2.5–2.8 N2.8
mPAP, mean pulmonary artery pressure.increased CO, after administration of a short-acting vasodilator, such
as nitric oxide (NO) [10], epoprostenol or adenosine [7].
4. Epidemiology
The incidence and prevalence of PAH were estimated to be 2.4–
7.6 cases/million/year and 15–26 cases/million, respectively, in large
population studies [11,12]. Worldwide prevalence is hard to appraise,
but it is surely underdiagnosed [13] and its onus is likely greater than
recognized, given the newly revealed associations with haemodialysis
[14], the metabolic syndrome [15], and developing world diseases,
such as human immunodeﬁciency virus (HIV) infection, schistosomi-
asis, and sickle cell disease [16]. Apart from iPAH no precise estimates
of incidence or prevalence are available. Nevertheless, non-PAH PH is
increasingly recognized as a major health burden. HF is the most
common cause of pulmonary hypertension (PH). Not only up to 60% of
patients with severe LV systolic dysfunction but also 70% of those with
HF and normal ejection fraction (EF) [17] develop PH [18,19].Moreover,
PH afﬂicts 70% of patients with rheumatic heart disease [20]. Many
patients develop chronic thromboembolic PH (CTEPH) after pulmonary
thromboembolism (PTE) [20] or PH during the progression of chronic
obstructive pulmonary disease (COPD). Prevalence ranges from 35 to
90% according to stage [21,22]. Systolic PAP (SPAP) is mostly limited to
values ranging from 25 to 35 mm Hg, and severe PH is uncommon in
advanced COPD [23]. Nevertheless, some patients develop dispropor-
tionate PH. Thesewarrant particular attention [21], but evenmodest PH
has a strong impact on quality of life (QOL) and survival [22]. Right HF,
its most severe complication, is responsible for 10–30% of admissions
due to decompensated HF [24]. Presently COPD is already responsible
for 84%of cor pulmonale cases and, due to smoking,will be the3 rd cause
of death by 2020 [23]. Portopulmonary hypertension (PPH) is a
pulmonary-hepatic vascular disorder that afﬂicts approximately 5–6%
of patients referred for liver transplantation due to advanced liver
disease. It is an underrecognized complication that adversely affects
survival, after liver transplantation but presumably also in the early
stages of liver disease [32,33].
5. Clinical presentation and workup
Severe disease may present with chest pain, palpitation, oedema,
ascites, and syncope [9] but earlier treatment, at reversible stages, is
fundamental. Diagnosis is challenging, a delay of 2 to 3 years is common
and a high suspicion level is needed [13]. The clinician may ﬁnd RV
hypertrophy on the electrocardiogram and hilar PA prominence on the
chest X-ray. Echocardiography, generally undertaken after a suspicion,
may show increased SPAP, estimated by the velocity of tricuspid
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is fundamental to evaluate valve or primary myocardial disease, as well
as the degree of RV hypertrophy and dysfunction [9]. Comprehensive
echocardiographic evaluations of RV function have been proposed as
useful approaches to risk stratiﬁcation in PAH [25], although magnetic
resonance imaging techniques have also been used [26]. Regarding
differential diagnosis, patientswith suspicion of PTE should undergo the
highly sensitive ventilation-perfusion (V-Q) scan. Staging and opera-
bility also relies on chest computerized tomography (CT) and
angiography. High-resolution CT is useful to assess PVOD or PCH and
to diagnose interstitial lung or connective tissue disease (CTD) [7,9].
Finally antinuclear antibodies, autoimmune disease markers, HIV and
viral hepatitis screening, coagulation disorder markers (eg, protein S
and C, lupus anticoagulants, von Willebrand factor) and type B
natriuretic peptide (BNP) may be carried out for differential diagnosis
[7,9]. The key feature differentiating PH resulting from left-heart disease
(LHD) is elevatedpulmonary capillarywedgepressure (PCWP),which is
absent in PAH [27]. To establish the diagnosis of PPH patients must
present with portal hypertension and not only haemodynamic criteria
for PH, in the absence of other causes, but also increased pulmonary
vascular resistance (PVR) [28]. Functional respiratory evaluation relies
on spirometry and carbon monoxide diffusion (DLCO). Spirometry may
be markedly altered in lung disease, whereas minor changes are found
in iPAH. DLCO impairment correlateswith lung vascular surface area and
PAH severity [29]. The 6-minute walk test (6MWT), a common clinical
trial end-point that evaluates moderate to severe heart or lung disease,
is an easily performable and reproducible test originally developed as a
surrogate of peak O2 consumption (Table 3). It correlates well with CO,
PVR, O2 consumption, QOL, and predicts mortality in PAH [30].Table 3
The 6-minute walk test (6MWT) in pulmonary hypertension (PH).
Features
Submaximal exercise test
Correlates well with activities of daily living (useful for moderately
severe functional impairment)
Non-speciﬁc (evaluates the response of all systems)
Well tolerated (nevertheless, appropriate response to an emergency
should be available)
Measurements
Dyspnoea and fatigue self-rating at the beginning and end
(according to the Borg scale, see legend)
Distance walked
Demographic and anthropometric determinants
Gender, age and ethnicity
Height and weight
Advantages
Practical and inexpensive to perform (no equipment or specially
trained technicians needed)
Reproducible (estimated coefﬁcient of variability of 8%)
Ongoing monitoring of cardiopulmonary disease progression
Evaluation of response to therapy
Limitations
Merely a rough estimate of the general functional status
(does not discard speciﬁc assessment tools)
Lack of validation for connective tissue disease associated PAH
(musculoskeletal involvement)
“Ceiling effect” for patients with better baseline capacity
Biases: disturbed cognition, motivational factors, test repetition,
musculoskeletal limitations, etc.
A comprehensive perspective on the 6MWT including indications, contraindications,
safety precautions, technical aspects, biases, can be found in the guidelines from the
American Thoracic Society [134]. The 6MWT measures the distance that a patient can
walk on a ﬂat surface in a period of 6 min, patients are allowed to stop and rest. The
normal walked distance for healthy 60 year-old men and women of average
constitution is approximately 630 and 550 m, respectively [135], whereas idiopathic
PAH patients on World Health Organization functional class IV usually walk less than
200 m [30]. A clinically important improvement in walking distance for the PAH patient
is generally 44–76 m [103].
Borg scale: (0) nothing at all, (0.5) just noticeable, (1) very slight, (2) slight, (3)moderate,
(4) somewhat severe, (5) severe, (7) very severe, and, ﬁnally, (10) maximal [136].Nevertheless, since it depends on many individual variables, it is not a
reliable marker of disease progression [7]. Additionally, its validity has
been questioned for CTD [31]. Cardiopulmonary exercise testing,
regarded by most as gold-standard in exercise capacity evaluation and
still a cornerstone in PAH functional evaluation, also assesses PH
prognosis [32], but requires an experienced laboratory [33,34].6. Pathophysiology
Although no animal model completely recapitulates human PAH,
combining multiple insults, according to the multiple-hit hypothesis,
yielded severe phenotypes that closelymimic it [35]. Pathophysiological
knowledge, derived mostly from these animal studies, once viewed PH
as an imbalance between pulmonary vasoconstrictors and vasodilators
[36]. While prostacyclin (PGI2) and NO normally govern vascular tone,
endothelin-1 (ET-1), thromboxaneA2 (TxA2) and serotonin (5-HT) take
over in PH. Not surprisingly, lung arteries vasodilators have been the
mainstay of therapy (Fig. 1) [3]. Nevertheless, recent research showed
this view to be highly incomplete.6.1. PAH as panvasculopathy
PAH is currently viewed as a panvasculopathy, accompanied by
histological features as intimal hyperplasia, medial hypertrophy, and
arteriolar occlusion by thrombosis, inﬁltration by inﬂammatory cells or
angioproliferative plexiform lesions (Fig. 1) [7]. Apoptosismay generate
apoptosis-resistant endothelial cell phenotypes that cross-talk with PA
smoothmuscle cell (PASMC) through growth factors such as transform-
ing growth factor-β (TGF-β), that are involved in endothelial cell and
ﬁbroblast transdifferentiation and PASMC proliferation [37]. Metallo-
proteinase activation leads to the disruption of thebasementmembrane
enabling inﬂammatory cell recruitment and further generation of
mitogenic peptides [38]. The main mechanisms involved in inﬂamma-
tion, endothelial progenitor cell (EPC) recruitment, growth factor
activity and extracellular matrix remodeling are summarized in Fig. 1.
PAH shares a mitochondrial-metabolic abnormality with cancer, the
“Warburg phenotype”, a shift from oxidative phosphorylation to
glycolysis (despite adequate O2 supply) that enhances proliferation
and prevents apoptosis (Fig. 2). Hyperpolarization of themitochondrial
membrane, reduced production of reactive oxygen species (ROS),
normoxic-activation of hypoxia inducible factor-1α, overexpression of
pyruvate dehydrogenase kinase (PDK) and decreased expression of O2-
sensitive K+ channels (Kv1.5) have been postulated to underlie changes
in mitochondrial O2 sensing [39]. PDK activation suppresses aerobic
glucose metabolism and decreased Kv1.5 conductance depolarizes the
membrane. Dichloroacetate (DCA), a mitochondrial PDK inhibitor and
Kv1.5 channel opener, improved PAH [39] both by activating pyruvate
dehydrogenase (PDH) and aerobic metabolism and by restoring
membrane potential and ROS production [40].6.2. Genetics of PAH
Mutations in bone morphogenetic protein (BMP) receptor-2
(BMPR2), a constitutively active receptor responsive to TGF-β super-
family (including BMP), are seen in more than 80% of familial PAH
(fPAH) cases, leading to loss of smad signalling (Fig. 3) and therefore to
increased proliferation and decreased differentiation of PASMC [41,42].
Still, penetrance is lowand themutation is seenonly in 10 to20%of non-
fPAH [43]. Other geneticmechanismspredispose to PAH, namely single-
nucleotide polymorphisms of Kv1.5 [18], transient receptor potential
(trp) channels [13], and serotonin transporters [44]. Trp channels
regulate contractility and cell proliferation by intracellular Ca2+[45].
Elevated 5-HT levels and 5-HT transport have been implicated in PAH
pathogenesis [44].
Fig. 1. Pulmonary artery smoothmuscle cell (PASMC) constriction and proliferation mechanisms. Themajor sites of action of lung vasodilator drug classes are shown in the upper panel,
namely Ca2+-channel blockers (CCB), endothelin-1 (ET-1) receptor antagonists (ERA), phosphodiesterase inhibitors (PDEi) and prostanoids. Myosin light-chain (MLC) kinase (MLCK) is
inactivated upon phosphorylation (MLCK-P). Other mechanisms are presented in the lower panel. Several cytokines, beyond interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α),
mostly produced by ﬁbroblasts, such as stromal cell-derived factor-1 (SDF-1), monocyte chemotactic protein-1 (MCP-1), fractalkine, RANTES (regulated upon activation, normal T
expressed and secreted), and vascular endothelial growth factor (VEGF) are upregulated and induce PASMC proliferation and monocyte recruitment, while monocytes upregulate the
α-chemokine receptor (CXCR4) and chemokine receptors 1, 2 and 5 (CX3CR1, CCR2 and CCR5, respectively) [46]. Elastase, early activated in PH, triggers growth factors release from the
extracellularmatrix (ECM) and induces tenascin C (TnC) through the activationofmatrixmetalloproteinases (MMP).WhenTnCbinds surface integrinsonPASMCscell-survival signals are
generatedandgrowth factor receptors are further activated. Serotonin (5-HT) inducesproliferationofPASMCsby stimulationof S100A4/Mts1, a S100Ca2+-bindingprotein familymember
withmetastasis-inducing ability [3]. Endothelial progenitor cells (EPC)may participate in vessel repair, but on the other hand also take part in plexiform lesions [146]. Other abbreviations:
TxA2, thromboxane A2; Gq, protein Gq; IP3, inositol 3-phosphate; SR, sarcoendoplasmic reticulum; ETA, ET-1 type A receptor; TP, TxA2 receptor; 5-HT2A, 5-HT type 2A receptor; CaL, Type L
Ca2+-channel; GC, guanylate cyclase; AC, adenylate cyclase; IP, prostacyclin receptor; PDE5, phosphodiesterase type 5; PKG, protein-kinase G; PKA, protein-kinase A; VEGFR, VEGF
receptor; PDGF, platelet derived growth factor; TGF-β, transforming growth factor-β; PDGFR, PDGF receptor; TGFβR, TGF-β receptor; EGFR, epidermal growth factor receptor.
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Fig. 2. Reactive oxygen species (ROS), disturbed O2 sensing, and mitochondrial dysfunction in pulmonary arterial hypertension (PAH). During oxidative phosphorylation, electrons (e−)
are conveyed by the electron transport chain (ETC) from donors (NADH and FAH) to O2, but minor side reactions also generate by-products, as superoxide anion (O2. −) that must be
detoxiﬁed to H2O2 by superoxyde dismutase (SOD) [147]. Under normoxiaH2O2 constitutively opens plasmamembrane O2-sensitive K+-channels (Kv1.5) and inhibits hypoxia-inducible
factor-1α (HIF-1α) activity, whereas during hypoxic vasoconstriction, ROS and H2O2 production are decreased, Kv1.5 channels close, the plasmamembrane depolarizes, Ca2+ enters the
cell andmyocytes contract. In PAH,mitochondrial abnormalities, most notably pyruvate dehydrogenase kinase (PDK) activation, shift metabolism toward anaerobic glycolysis and impair
the ETC. Reduced ROS production, nuclear translocation of HIF-1α, and decreased expression of Kv1.5 ultimately lead to sustained membrane depolarization, L-type Ca2+-channel (CaL)
activation and hypertrophy by Ca2+-calcineurin-dependent activation of the nuclear factor of activated T lymphocytes (NFAT) [146]. PDH, pyruvate dehydrogenase, and respective
phosphorylated form (−P); ET-1, endothelin-1; VEGF, vascular endothelial growth factor.
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The inﬂammatory state of the vessel wall has recently gained
interest as primary event, rather thanmere consequence of the disease
[46]. Autoantibodies and inﬁltration by inﬂammatory cells are
common in PAH associated with CTD but are also seen in iPAH [46].
Increased levels of cytokines and their receptors have been demon-
strated, particularly in iPAHpatients [47],who also present heightened
expression of inﬂammatory cell-associated nuclear factor of activated
T lymphocytes (NFAT) [48]. Cytokines involved in the pathogenesis of
chronic inﬂammatory diseases and cancer, such as tumor necrosis
factor-α (TNF-α) and IL-6, may play a role in PAH vasculopathy [49].
Our group has tested an anti-inﬂammatory approach in experimental
models of PH with variable success [50,51]. Inﬂammatory activation
may also underlie systemic manifestations, for instance cardiac
cachexia (CC). CC is characterized not only by neuroendocrine and
inﬂammatory activation but also by suppressed appetite and nutri-
tional derangements [52] and poses a signiﬁcant prognostic burden on
HF patients [53]. CC accompanies the progression of PH, indeed,
patients with severe PH have exaggerated and early post-prandial
satiety hormone response [54].
6.4. The RV in PH
The RV effectively serves as a thin, compliant reservoir for blood
returning to the LVwhose primary function of is to deliver deoxygenated
blood to the lungs, while maintaining low-pressure perfusion [55]. It is
thus best suited for volumework and unable to suddenlywithstand high
PAP. Sudden afterload decreases stroke volume and dilates the RV [56],
whereas progressive overload allows gradual hypertrophy, remodeling
and substantial increases in mPAP. Curiously, although RV response
partly determines the outcome [26,57], despite the fact that the RV was
shown to be an independent therapeutic target in experimental PH [58],and even though RV remodeling is potentially reversible, as seen after
lung transplantation (LT) [59], little is known about the mechanisms
underlying RV dysfunction [55]. Many have shown neuroendocrine
activation can contribute to RV hypertrophy [60,61], ﬁbrosis and
apoptosis, as well as to oxidative stress, and activation of inﬂammatory
cytokines and growth factors [55,62]. A state of myocardial hibernation
has been proposed based on systolic ﬂow impediment to coronary
arterieswhich is proportional toRVpressure andmass [63]. In contrast to
the normal ﬂexible metabolism, in RV hypertrophy the myocardium
relies solely on anaerobic glucose metabolism partly due to PDK
activation [64] and possibly impaired mitochondrial energy-producing
ability [65]. Moreover, changes in cardiomyocyte redox state can
underlie electrophysiological instability and remodeling, bymechanisms
similar to those already described for pulmonary vessels [66]. Experi-
mental ﬁndings and clinical observations suggest that elevated mPAP
cannot be the single driver for RV failure [62], therefore, targeting the RV
may be a promising approach [6]. As for the LV myocardium,
echocardiography shows compromised LV function in various aetiol-
ogies of PH [67], mainly due to ventricular interdependence and
impaired ﬁlling [68]. Nevertheless, myocardial abnormalities partly
underlie LV dysfunction. Indeed, despite immediate restoration of LV
geometry and RV function, LV ﬁlling is only normalized 1 year after
single-LT in severe PH [69], and combined heart-lung transplantation
(HLT) is favored if LV function is impaired because the LV may not
recover after LT alone [70]. We have conﬁrmed intrinsic LV myocardial
dysfunction and neuroendocrine activation experimentally [61,71].
6.5. Pathophysiology of non-PAH PH
Contrarily to PAH, and paradoxically, few data are available on the
pathophysiology of the far more common non-PAH PH. Regarding
chronic pulmonary disease, several mechanisms are potentially
responsible. Hypoxia, such as is found at high altitude, is known to
Fig. 3. Growth-promoting pathways in bone morphogenetic protein (BMP) receptor
type 2 (BMPR-2) mutations. Bone morphogenetic protein (BMP) receptor type 1
(BMPR-1) and -2 dimerize upon activation by BMP and initiate a cytosolic receptor-
activated Smad protein-signaling cascade. Smads (homology with drosophila's mothers
against decapentaplegic –MAD – and Caenorhabditis elegans' small phenotype – sma –
proteins) ultimately complex with common partner Smad4 and translocate to the
nucleus. The weak Smad–DNA interaction requires co-repressors or activators
(Co–A/R) [148]. Signal disrupting mutations in BMPRII can be found in the ligand-
binding domain, in the kinase domain or in the cytoplasmic tail. Suppression of Smad
signalling partly underlies the hypertrophic and proliferative phenotype of pulmonary
artery smooth muscle cells (PASMC) [149]. In normal PASMC, BMP stimulates
transcriptional activation of cyclin-dependent kinase (CDK) inhibitors and repression
of c-myc. CDK inhibitor prevents progression in cell cycle, while c-myc encodes a
transcriptional activator responsible for growth and proliferation [150]. Inhibitor of
DNA (Id) binding proteins, a family deprived of DNA-binding domain that acts by
inhibition of transcription factors, are also major targets. Failure to induce Id genes
makes PASMC unresponsive to the growth suppressive effects of BMPs [151].
Prostanoids, by cyclic adenosine monophosphate and a direct effect on the Id promoter,
drive the expression of Id proteins [148].
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mPAP, therefore after the Evian Conference COPD-associated PH was
no longer classiﬁed as ‘associated with hypoxemia’ [29]. Pulmonary
vessels in COPD consistently develop intimal ﬁbro-elastic thickeningand overall muscularisation but this does also not provide a consistent
explanation [72]. Endothelial dysfunction and inﬂammation, are
currently viewed as the key to vascular remodeling [73]. Findings
strongly suggest an involvement of vasoactive mediators and cytokines
[72]. Plasma IL-6 correlates with mPAP and certain IL-6 genotypes are
associated with PH development in COPD [74]. Indeed, vascular
remodelling and endothelial dysfunction can be observed in mild
COPDwithout hypoxaemia and in ordinary smokers [75]. Symptomatic
CTEPH affects 3.8% of patientswithin 2 years of initial PTE [76], but up to
5.1% of patients may develop deﬁnite CTEPH [77]. Unlike PAH, CTEPH is
mainly associated with obstructions in larger vessels. Its pathophysiol-
ogy remains obscure, while most argue that it results from recurrent
pulmonary embolism, it has also been suggested that endothelial
dysfunction could lead to thrombus formation in situ, and, in fact many
patients donot have a clear history of embolism [78]. Variabledegreesof
small vessel disease, a PAH-like vasculopathy, accompany CTEPH and
the mechanisms that underlie them are probably common to PAH,
namely endothelial dysfunction [79]. As for LHD, two major mecha-
nisms underlie PH, an hydrostatic and a vasoreactive. Increased ﬁlling
pressures are transmitted to the pulmonary circulation and generate,
initially, pulmonary venous hypertension, but, later on, also PVR
increase. SPAP correlates tightly and is roughly twice the PCWP [80].
When the compensatory mechanisms of the highly distensible
pulmonary vasculature are surpassed PA pressure increases ﬁrst on
exertion and later on also at rest. Endothelial dysfunction, sympathetic-
adrenergic stimulation and disturbances of 5-HT, TxA2 and angiotensin-
II production further aggravate PH [81], contributing to structural
changes at the capillary level, namely swelling of the endothelial cells,
thickening of the basal lamina, and proliferation of reticular and elastic
ﬁbrils. These changes participate in increasing PVR, decreasing
permeability of the vascular bed, and lower the possibility of developing
pulmonary edema, but ultimately lead to increased likelihood of right
ventricular failure [82]. These changes are initially reversible if cardiac
ﬁlling pressures are reduced, but on the long term become irreversible
and pose a relative contraindication to cardiac transplantation [83].6.6. Prognosis
Although PAH has been most extensively studied, its rarity, diverse
etiology and changing therapeutics preclude an estimation of yearly
mortality rates. An early registry followed 194 patients with iPAH from
1981 to 1985 and estimated a median survival of 2.8 years, with 1-, 3-,
and 5-year survival rates of 68, 48, and 34%, respectively [84]. Present-
day registries, however, reveal a better prognosis, with 1 year survival
ranging 83 to 88% and 3 year survival 58 to 72% [85]. A risk-prediction
equation could be derived frommultivariate analysis, including gender,
6MWT, and CO at diagnosis as covariates [86]. Four variables were
associated with increased 1-year survival: WHO functional class I,
6MWT≥440 m, BNPb50 pg/mL, and DLCO≥80% of predicted [86].
Recently, echocardiographic evaluation of RV function has also been
successfully used for risk stratiﬁcation in PAH [25]. The progression in
non-PAH PH is generally slower and the overall prognosis is better. Still,
there is a substantial impact on QOL and survival [22,27]. The level of
PAP is a good indicator of prognosis in COPD and a 50% 5-year survival
rate has been reportedwith PH [87]. RegardingCTEPH, survival changed
dramatically. Before the advent of pulmonary endarterectomy (PEA)
patients who had mPAP higher than 30 mm Hg steadily progressed to
PH and 2 year-survival was lower than 20% after it reached 50 mm Hg
[88]. Currently, in experienced centres and carefully selected patients,
PEA provides remarkable haemodynamic and clinical improvement
with low procedural mortality rate [5]. In severe HF, the EF of the RV is
the most important determinant of short-term prognosis among
hemodynamic variables [89]. Although increased mPAP is frequently
coupledwith reduced RV function, exceptionsmust be taken in account
during prognostic stratiﬁcation [19].
Table 4
Summary of randomized clinical trials (RCT) on pulmonary arterial hypertension (PAH).
Class Drug Year Author Study type Sample Patients Follow-up Positive outcomes
Prostanoid Epoprostenol 1996 Barst [96] RCT (not blind) iPAH (WHO III–IV) 81 12 weeks Haemodynamics, QOL,
WHO class, survival
Treprostinil (sc) 2002 Simmoneau [98] RCT iPAH, CTD and CHD
(WHO II-IV)
470 12 weeks Haemodynamics, 6MWT,
clinical evaluation
Iloprost (inh) 2002 Olschewski [99]
(AIR)
RCT iPAH, CTD and CTEPH
(WHO III-IV)
203 12 weeks Haemodynamics, 6MWT,
QOL, WHO class
Beraprost 2002 Galiè [137]
(ALPHABET)
RCT iPAH, CTD, CHD, portal
hypertension
and HIV (WHO II-III)
130 12 weeks Exercise tolerance, 6MWT,
clinical evaluation
2003 Barst [138] RCT iPAH, CTD and CHD
(WHO II-III)
116 1 year Exercise tolerance, 6 MWT,
TTCW,
ERA Bosentan 2002 Rubin [103]
(BREATHE1)
RCT iPAH, CTD or SLE
(WHO III-IV)
213 16–28 weeks Exercise tolerance, 6MWT,
WHO class, TTCW;
2005 McLaughlin [139] RCT (not blind) iPAH (WHO III-IV) 169 3 years Survival (NIH prediction)
2006 Galiè [140]
(BREATHE5)
RCT CHD (WHO III) 54 16 weeks Haemodynamics, 6 MWT
2008 Galiè [106]
(EARLY)
RCT iPAH, CTD, CHD, HIV
(WHO II)
185 6 months Haemodynamics,
NT-pro-BNP and TTCW
2008 Jais [123]
(BENEFIT)
RCT CTEPH (WHO II–IV) 157 16 weeks Haemodynamics
Ambrisentan 2005 Galiè [141] RCT (dose ranging) iPAH, CTD, HIV and
anorexigen
(WHO II–III)
64 12+12 weeks
(not-blind)
Haemodynamics, 6 MWT,
clinical evaluation
2008 Galiè [142]
(ARIES 1 and 2)
RCT iPAH, CTD, HIV and
anorexigen
202+192
(parts 1 and 2)
12 weeks 6MWT, WHO class, QOL,
TTCW, NT-pro-BNP
2009 Oudiz [108]
(ARIES 1, 2 and E)
RCT iPAH, CTD, HIV and
anorexigen
383 2 years 6MWT, TTCW and survival
(combined outcome)
Sitaxsentan 2004 Barst [143]
(STRIDE1)
RCT iPAH, CTD and CHD
(WHO II–IV)
178 12 weeks Haemodynamics, 6MWT,
WHO class
2006 Barst [144]
(STRIDE2)
RCT iPAH, CTD and CHD
(WHO II–IV)
245 18 weeks 6MWT, WHO class
PDEi Sildenaﬁl 2005 Galiè [110]
(SUPER1)
RCT iPAH, CTD and CHD
(WHO II–IV)
278 12 weeks Haemodynamics, 6MWT,
WHO class
Tadalaﬁl 2009 Gàlie [145]
(PHIRST)
RCT (dose ranging) iPAH, CTD, CHD, HIV and
anorexigen
405 16 weeks Haemodynamics, WHO
class, 6MWT, TTCW, QOL
Combined Bosentan+Iloprost (inh) 2006 McLaughlin [114]
(STEP)
RCT iPAH, APAH (WHO III) 67 12 weeks Haemodynamics, WHO
class, TTCW
Epoprostenol+
sildenaﬁl
2008 Simmoneau
[115] (PACES)
RCT iPAH and CTD 267 16 weeks Haemodynamics, exercise
tolerance, QOL, TTCW
Bosentan or sildenaﬁl+
treprostinil (inh)
2010 McLaughlin [100]
(TRIUMPH I)
RCT iPAH, CTD, HIV and
anorexigen (WHO III–IV)
255 12 weeks QOL, NT-pro-BNP
RCT on PAH therapeutics are summarized according to drug class, drug type and publication date. Study acronyms are presented when applicable. Studies enrolling less than 50
patients as well as studies involving speciﬁc PAH groups, namely HIV-related and portal hypertension-related were excluded. iPAH, idiopathic pulmonary arterial hypertension;
WHO,World Health Organization; QOL, quality of life; 6MWT, 6-minute walk test; NIH, National Institute of Health; APAH, disease associated pulmonary arterial hypertension; CTD,
connective tissue disease APAH; CHD, congenital heart disease APAH; CTEPH, chronic thromboembolic pulmonary hypertension; HIV, human immunodeﬁciency virus APAH; TTCW,
time to clinical worsening; SLE, systemic lupus erythematosus APAH; NT-pro-BNP, N terminal fragment of pro-type B natriuretic peptide. Study acronyms stand for: AIR, Aerosolized
Iloprost Randomized; ALPHABET, Arterial Pulmonary Hypertension and Beraprost European Study Group; BREATHE, Bosentan Randomized trial of Endothelin Antagonist THErapy
Study Group; EARLY, Endothelin Antagonist tRial in miLdlY symptomatic PAH patients; BENEFiT, Bosentan Effects in iNopErable Forms of chronic Thromboembolic pulmonary
hypertension; ARIES, Ambrisentan in pulmonary hypertension, randomized, double blinded, placebo controlled, multicenter, efﬁcacy studies); STRIDE, Sitaxsentan To Relieve
ImpaireD Exercise; SUPER, Sildenaﬁl Use in Pulmonary Arterial Hypertension Study Group; PHIRST, Pulmonary Arterial Hypertension and Response to Tadalaﬁl; STEP, Safety and
pilot efﬁcacy Trial in combination with bosentan for evaluation in pulmonary arterial hypertension; PACES, pulmonary Arterial hypertension Combination study of epoprostenol and
sildenaﬁl; TRIUMPH I, efﬁcacy and tolerability of inhaled Treprostinil sodium in patients with severe pulmonary arterial hypertension.
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Treatment of PAH has evolved considerably over the past decade,
many treatment algorithms have been proposed, mainly based on
studies conducted in patients with iPAH and PAH associated with
CTDs. In Table 4 we summarize the major therapeutic studies on PAH.
Several general measures can be recommended. Regarding
exercise practice, patients may practice low level aerobic exercise,
such as walking, whereas exertion that may lead to breathlessness,
dizziness or chest pain should be avoided. Some patients may not
tolerate high altitudes, for instance during airplane ﬂights, and
therefore require in-ﬂight O2 administration. It is currently recom-
mended for patients either in WHO classes III and IV or whose arterial
O2 pressure is below 60 mm Hg. Dietary sodium restriction can be
advised particularly in RV failure (≤2.4 g.d−1), but current EuropeanSociety of Cardiology guidelines do not recommend it. Immunization
against common respiratory pathogens is recommended [7]. PAH is a
contraindication to pregnancy due to the high mortality rate [90].
Despite the lack of randomized controlled trials (RCT), the initial
therapeutic, and largely supportive, approaches to the treatment of
PAH were anticoagulation, diuretics, O2 therapy and digoxin. Obser-
vational studies suggested improved survival after anticoagulation in
patients with iPAH, therefore most experts recommend anticoagula-
tion in iPAH, heritable PAH, and PAH due to use of anorexigens
(titrated to international normalized ratio of 2.0–3.0). As for non-iPAH,
anticoagulationmay be advised for severe cases [7]. Diuretics are used
tomanageHF symptoms. O2 therapy inhypoxemia is employed strictly
to avoid vasoconstriction. Based on a short-term effect study, digoxin
may be used in patients with low CO, but its use is clearly only
recommended in patients with supraventricular tachyarrhythmias
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research have yielded several new and more effective alternatives to
treat PH. The main pharmacological classes will be brieﬂy presented.
Most of the studies are small scaled and short-termed, not suitable for
survival analysis, but a recentmeta-analysis found an overall beneﬁt in
mortality [92]. Nevertheless, most therapies reducemPAP by only 10–
20%, with the exception of strong responders to CCB. Despite all the
advancement, many patients still remain symptomatic, with a
suboptimal QOL and warrant combined therapy or even invasive or
surgical procedures.
7.1. Ca2+ channel blockers
Amarked improvement in survival rateswas shownwith long-term
high-dose CCB therapy for patients with iPAH and a positive
vasoreactivity test [93]. Long acting nifedipine, diltiazem, or amlodipine
aremore commonlyused. If there is no recovery to functional classes I or
II patients are deemed as non-responders and should discontinue CCB.
True responders are rare in non-iPAH [94]. Indiscriminate use is not
recommended, due to systemic vasodilation and negative inotropic
effects [95].
7.2. Prostanoids
There are presently several commercially available prostanoid
formulations. Intravenous (iv) epoprostenol was the ﬁrst shown to
improve functional class, hemodynamics and survival in a 12-week
follow-up period in patients with iPAH of classes III and IV [96]. These
beneﬁcial effects were reproduced in long-term observational compar-
isons with historical controls [97]. Moreover, epoprostenol was also
evaluated in CTD associated PAH and other forms of non iPAH with
favourable outcomes. Presently, because of the complex administration
and cumbersome follow-up, epoprostenol use is mainly conﬁned to
highly experienced centres. Patientsmust keep a central venous catheter
(CVC) and handle drug preparation and infusion. Dosing must be
carefully titrated.Most patients dowellwith an initial in-hospital dose of
2 ng.kg-1.min-1 and a dose range between 25 and 40 ng.kg−1.min−1.
Unfortunately, substantial side-effects have been reported, namely
ﬂushing, headache, and sudden death after abrupt discontinuation, as
well as risk of infection related to CVC [7]. Treprostinil, a longer half-life
prostanoid, amenable to administration by subcutaneous (sc) route,
circumventing the need for CVC, showed minor beneﬁcial effects in
patients with functional classes II–IV of idiopathic, CTD and (CHD)
associated PAH [98]. The Food and Drug Administration (FDA) approved
it for functional classes II–IV also by iv route, when the sc route is not
tolerated due to pain or erythema. It is currently not approved by the
European Medicines Agency (EMA). On another attempt to facilitate
administration, iloprost was developed for inhalation by aerosol device.
After a 12-week administration, iloprost improved the 6MWT and
functional class in a multicentre RCT enrolling patients with PAH of
different aetiologies [99]. Treprostinil is now also available by inhalation
[100], and trials of oral formulations have been iniciated (FREEDOM,
Trial of Oral Treprostinil in Pulmonary Arterial Hypertension).
7.3. Endothelin receptor antagonists
We have previously reviewed the role of ET-1 and its antagonists
(ERA) in cardiovascular pathophysiology [101]. Brieﬂy, after a small
magnitude RCT had shown improvement in the 6MWT, mPAP and CO
with the non-selective ERA bosentan [102], a larger scale study
conducted in patients with idiopathic or CTD associated PAH,
reproduced theseﬁndings and reported improvement in time to clinical
worsening (TTCW), a secondary endpoint deﬁned as a composite of
mortality, LT, hospitalization, discontinuation due to lack of recovery or
need for epoprostenol or atrial septostomy (AS) [103]. As an important
side-effect, bosentan dose-dependently altered hepatic function. Ane-mia can also occur and the FDA therefore recommends liver function
test and haematocrit surveillance [7]. Long-term evaluation as a ﬁrst-
line drug in functional class III patients also revealed good results,
althoughmany patients demanded prostanoids [104]. In fact, improved
survival was only demonstrated by comparison with historical data
from epoprostenol treated iPAH WHO class III patients, and unfortu-
nately the twocohortswerenot comparable [105]. Bynow,bosentanhas
also been tested in CHD, HIV-associated PAH and CTEPHwith favourable
results.Moreover, it hasbeen successfullyused ina large sampleofmildly
symptomatic, class II, multiple cause-PAH patients improving haemody-
namics and TTCW [106]. Sitaxentan a selective ETA ERA initially was
shown to have comparable effects to bosentan in iPAH and PAH
associated with CTD or CHD, but has been withdrawn from market due
to two fatal casesof liver failure [107]. Ambrisentan, another selectiveETA
ERA, also improved the 6MWT and TTCW, which was reproducible in
long-term studies [108]. It is approved by the FDA since 2007 and it has
also been approved by the EMA for PAH patients in functional classes II
and III. Indeed, it is the only ERA approved for WHO class II.
7.4. Phosphodiesterase inhibitors
Phosphodiesterases (PDE) degrade cyclic guanosine monopho-
sphate (cGMP) therefore PDE inhibitors (PDEi) potentiate the effects
of cGMP generated by NO activation of guanylate cyclase. NO and NO
donorshavebeen extensivelyused as a rescue therapy tomitigatemPAP
in the perioperative period and in the critically ill patient, particularly in
children [109]. Sildenaﬁl, the ﬁrst used PDEi, was shown to improve
6MWT, WHO functional class and mPAP in idiopathic, CTD or CHD
associated PAH, but there were no differences in TTCW [110]. The FDA
approved sildenaﬁl in low doses for patients with PAH although there is
some debate as to whether higher doses might confer additional
beneﬁts [111]. Other PDEi are currently under study. Tadalaﬁl, recently
approved by both FDA and the EMA, has a longer half-life than sildenaﬁl
and is amenable to once-daily dosing. Nevertheless, unlike sildenaﬁl,
due to its hepaticmetabolism and renal clearance, dose adjustments are
recommended for patients with renal or hepatic function impairment
[112].
7.5. Combination therapy
The possibility to combine distinct drug classes that target different
molecular pathways in order to improve clinical efﬁcacy and minimize
side-effects is an attractive perspective. After an initial attempt to
combine bosentan and epoprostenol in a small scale and underpowered
trial conducted on patients with either iPAH or PAH associated to CTD
that proved unsuccessful [113], another trial that combined inhaled
iloprost with bosentan in patients who remained symptomatic showed
improvement in functional class, TTCW and haemodynamics [114].
More recently, the addition of sildenaﬁl to PAH patients who remained
symptomatic ona stabledoseof ivepoprostenol improved the6MWT, as
well as mPAP, CO, and TTCW [115], while the addition of inhaled
treprostinil toWHO III and IV PAH patients undergoing either bosentan
or sildenaﬁl chronic therapy showed only clinical beneﬁts in QOL [100],
and the introduction of oral treprostinil failed to achieve statistical
signiﬁcance in 6MWT (FREEDOM, unpublished results).
7.6. Invasive and surgical strategies in PAH
These include AS and LT or HLT. Other possibilities, such as the RV
mechanical assist devices (RVAD) are still poorly investigated. AS creates
a right-to-left shunt that unloads the RV, decreasesmPAP, and improves
LV ﬁlling. The increase in CO offsets the shunting of deoxygenated blood
and ameliorates O2 delivery. Increased CO allows bridging to transplan-
tation in up to 40% of patients [116]. Nevertheless, it is merely palliative
and procedural mortality is still high therefore it is just a last resort for
patients on maximal medical therapy and inotropic support. Improved
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Currently, PAH is responsible for approximately 4% of LT and HLT, and
although there is a substantial procedural related mortality, the long-
term outcome is better than with medical therapy alone, with a 47%
survival after 5 years [117]. The type of transplant is still a matter of
debate andhighly related to the experienceof each centre. GenerallyHLT
is preferred either when patients have intractable HF or are dependent
on inotropic support or if PH is secondary to CHD or LHD [70].
7.7. Therapeutic algorithm
Management must be tailored to each patient according to disease
severity, comorbid conditions, drug side-effects and each centre's
experience. CCB are reserved for iPAH patients with a positive
vasoreactivity test and stable hemodynamics, otherwiseﬁrst line therapy
should consist of ERA or PDEi, unless the oral route is not available,
patients are in functional class IV or present overt RV failure. In these
cases, the ﬁrst choice is an iv prostanoid.Moreover, combination therapy
should always be kept in mind, particularly when side-effects arise or
patients are not responding. Enrolment in clinical trials with newer
pharmacological agents may be an option but AS and transplantation
should be considered before systemic deterioration. Early referral for
transplantation is crucial particularly for refractory cases [7]. A simpliﬁed
therapeutic algorithm is suggested in Fig. 4.
7.8. Non-PAH PH
Patients will beneﬁt from medical optimization of their primary
disease, but signiﬁcant PH may persist. Some patients actually present
disproportionate PH not easily attributable to the underlying condition.
In left-heart disease prostanoids, with the exception of inhaled route,
are usually contraindicated due to systemic vasodilation [118]. ERA trials
have been interrupted prematurely due mainly to side-effects and
absence of clinical beneﬁt, even with reduced dose [119], but selected
casesmaybeneﬁt fromshort trials as a bridge to transplantation [120]. AsFig. 4. Algorithm for pulmonary arterial hypertension (PAH) management. CCB,
calcium channel blockers; WHO, World Health Organization; ERA, endothelin-1
receptor antagonists; PDEi, phosphodiesterase inhibitors; RCT, randomized clinical
trials; iv, intravenous; sc, subcutaneous. *, among the ERAs only ambrisentan is
approved for WHO class II patients.for PDEi short-term hemodynamic beneﬁts, as well as long-term
improvements have been documented [121].
Mild levels of PH are amenable to optimization of medical therapy in
COPD. If PH is disproportionate, andother PH causes have been ruled out,
many centres are routinely employing vasodilators despite V-Q
mismatch [122]. CTEPH is potentially curable with PEA [5]. Yet, many
patients are not candidates so they remain anticoagulated and on
diuretics. Many centres are promptly using new PAH drugs off-label if
there is associated vasculopathy [123].
7.9. Recent progresses and future targets in PH
Based upon the most recent experimental ﬁndings, clinical trials
targeting alteredmetabolic and signalling pathways are warranted. DCA
and Kv1.5 channel gene transfer have been successful in experimental
studies [39], as well as trp channel inhibitors, growth factor receptor
inhibitors and intracellular kinase inhibitors [3,124]. Inﬂammatory
response modulation has also been a major research topic. After several
animal studies demonstrating beneﬁcial effects of statins [124], possibly
due to pleiotropic effects, a human study disappointingly showed no
long-lasting improvement [125]. Other immunomodulatory agents have
been successful in animal experiments [50,126], but beneﬁcial effects are
mainly conﬁned to CTD associated PAH [127]. We have also reported
disturbances in endogenous endocrine and paracrine systems [128,129]
that may be targeted. Another tempting possibility is the recruitment or
infusion of EPC. The number and function of EPCs predicts prognosis, and
most currently used drugs increase circulating EPC numbers [130].
Circulating EPCs home to sites of endothelial injury, promote revascu-
larization and improve vascular homeostasis [131], endothelial dysfunc-
tion may be related to the lack of EPCs [130]. Finally, we must bear in
mind that RV failure is the ﬁnal and most severe complication of PH.
Agents such as levosimendan that vasodilate lung vessels but are also
positive inotropes are predictably good therapeutic tools. Still, theclinical
efﬁcacy of these drugs has only just started to be evaluated [132,133].
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